Alaunos Therapeutics Says It Regains Compliance With Nasdaq Stockholders' Equity Requirement
Bitget2026/10/21 20:35- Alaunos Therapeutics believes it has regained compliance with Nasdaq’s $2.5 million minimum stockholders’ equity requirement.
- A $350 million financing closed October 14, 2026, bolstering equity alongside a cash settlement waiver covering approximately $9 million of preferred stock.
- Nasdaq confirmation remains pending; a delisting hearing scheduled for November 10, 2026, is expected to be canceled upon confirmation.
- Continued listing remains at risk if the fiscal 2026 annual report fails to demonstrate compliance.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries
A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.
Quantumrail Cancels 10 Billion Won Convertible Bond Offering
Crypto prices
More
